DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Label-free immunodetection of α-synuclein by using a microfluidics coplanar electrolyte-gated organic field-effect transistor
The aggregation of α-synuclein is a critical event in the pathogenesis of neurological diseases, such as Parkinson or Alzheimer. Here, we present a label-free sensor based on an Electrolyte-Gated Organic Field-Effect Transistor (EGOFET) integrated with microfluidics that allows for the detection of amounts of α-synuclein in the range from 0.25 pM to 25 nM. The lower limit of detection (LOD) measures the potential of our integrated device as a tool for prognostics and diagnostics. In our device, the gate electrode is the effective sensing element as it is functionalised with anti-(α-synuclein) antibodies using a dual strategy: i) an amino-terminated self-assembled monolayer activated by glutaraldehyde, and ii) the His-tagged recombinant protein G. In both approaches, comparable sensitivity values were achieved, featuring very low LOD values at the sub-pM level. The microfluidics engineering is central to achieve a controlled functionalisation of the gate electrode and avoid contamination or physisorption on the organic semiconductor. The demonstrated sensing architecture, being a disposable stand-alone chip, can be operated as a point-of-care test, but also it might represent a promising label-free tool to explore in-vitro protein aggregation that takes place during the progression of neurodegenerative illnesses., This work was funded by the EXPLORA project MAT2015-72760-EXP (Spanish Ministry) and ERC StG 2012–306826 e-GAMES (European Research Council FP7). The authors also thank the Spanish Ministry of Economy and Competitiveness, through the projects FANCY CTQ2016-80030-R, GENESIS PID2019-111682RB-I00 and “Severo Ochoa” Programme for Centers of Excellence in R&D (SEV-2015-0496), the Generalitat de Catalunya (2017-SGR-918) and the Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN). S. R. is enrolled in the PhD program of the Universitat Autònoma of Barcelona (UAB). The research leading to these results has also received funding from the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007–2013) under Research Executive Agency Grant Agreement No. 600388 (TECNIOSpring programme), and from the Agency for Business Competitiveness of the Government of Catalonia, ACCIÓ. The Surface Plasmon Resonance (SPR) measurements were performed through the ICTS NANBIOSIS platform, more specifically in the Biodeposition and Biodetection Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) at the Catalan Institute of Nanoscience and Nanotechnology (ICN2). The microfluidic device design and fabrication were performed with funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 764281 (AiPBAND), and Marie Skłodowska-Curie grant agreement 813863 (BORGES)., Peer reviewed
Project:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 MAT2015-72760-EXP
,
EC / FP7 306826
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 CTQ2016-80030-R
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-111682RB-I00
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SEV-2015-0496
,
EC / FP7 600388
,
EC / H2020 764281
,
EC / H2020 813863
View at: http://hdl.handle.net/10261/228042